Roger Grau

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 957 citations · Full text

Life Sciences, Immunology, Oncology +17

Direct Genetic Analysis of Single Disseminated Cancer Cells for Prediction of Outcome and Therapy Selection in Esophageal Cancer

Nikolas H. Stoecklein, Stefan B. Hosch, Martin Bezler et al. · Cancer Cell · 2008 · 206 citations · Full text

Life Sciences, Genetics, Oncology +17

Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a

E. Arduin, Shilpi Arora, P.R. Bamert et al. · Molecular Immunology · 2014 · 81 citations

Life Sciences, Immunology, Molecular Biology +8

A Novel, Blocking, Fc-Silent Anti-CD40 Monoclonal Antibody Prolongs Nonhuman Primate Renal Allograft Survival in the Absence of B Cell Depletion

Francisco Córdoba, Grazyna Wieczorek, M. Audet et al. · American Journal of Transplantation · 2015 · 80 citations · Full text

Medicine, Immunology, Nephrology +17

Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.

Pablo Umaña, Ekkehard Moessner, Peter Bruenker et al. · Blood · 2006 · 52 citations

Pharmacy, Biotechnology, Immunology +17